Use of placental therapy in the correction of functional impairments in women: investigations and clinical practice
Combination therapy for female functional disorders, which is aimed at both correcting pathological conditions and improving the quality of life, is the most important task of modern gynecology. Hormone therapy that is effective in many of these disorders is often ineffective and/or unacceptable for several reasons, and there is a need to search for alternative methods and approaches. One of these approaches is the use of organ preparations as a human placental extract. One placental drug Melsmon manufactured by Melsmon Pharmaceutical Co., Ltd., Japan, has been registered in Russia for gynecological indications. The goal of this paper is to generalize the experience in conducting clinical trials and using placental drugs in medical practice and to outline the prospects for their further trials and application. Melsmon that has proven to be effective and safe for menopausal syndrome, is being tested and used in the combination correction of diseases, such as genitourinary syndrome of menopause, premature ovarian failure, and in the maintenance therapy of gynecological cancer patients to increase the implantation susceptibility of the endometrium in infertility.Apolikhina I.A., Saidova A.S., Baranov I.I.
Keywords
menopausal syndrome
clinical trials
placental therapy
References
- Кулаков В.И., Вихляева Е.М., ред. Менопаузальный синдром. М., 1996. 66 с. [Kulakov V.I., Vikhlyaeva E.M., eds. Menopauzal’nyi sindrom. Moscow, 1996. 66p. (in Russian)].
- Сметник В.П. Системные изменения у женщин в климактерии. Русский медицинский журнал. 2001; 9(9): 354–61. [Smetnik V.P. Sistemnye izmeneniya u zhenshchin v klimakterii. Russkii meditsinskii zhurnal. 2001; 9(9): 354–61. (in Russian)].
- Zheng J., ed. Recent advances in research on the human placenta. IntechOpen; 2012.
- Banerjee K.K., Bishayee A., Chatterjee M. Anti-inflammatory effect of human placental extract: A biochemical mechanistic approach. Riv. Eur. Sci. Med. Farmacol. 1992; 14(6): 361–6.
- Togashi S., Takahashi N., Iwama M., Watanabe S., Tamagawa K., Fukui T. Antioxidative collagen-derived peptides in human placenta extract. Placenta. 2002; 23(6): 497–502. https://dx.doi.org/10.1053/plac.2002.0833.
- Рogozhykh O., Prokopyuk V., Figueiredo C., Pogozhykh D. Placenta and placental derivatives in regenerative therapies: experimental studies, history, and prospects. Stem Cells Int. 2018; 2018: 4837930. https://dx.doi.org/10.1155/2018/4837930.
- Lee Y.K., Chung H.H., Kang S.B. Efficacy and safety of human placenta extract in alleviating climacteric symptoms: prospective, randomized, double-blind, placebo-controlled trial. J. Obstet. Gynaecol. Res. 2009; 35(6): 1096–101. https://dx.doi.org/10.1111/j.1447-0756.2009.01066.x.
- Kong M.H., Lee E.J., Lee S.Y., Cho S.J., Hong Y.S., Park S.B. Effect of human placental extract on menopausal symptoms, fatigue, and risk factors for cardiovascular disease in middle-aged Korean women. Menopause. 2008; 15(2): 296–303. https://dx.doi.org/10.1097/gme.0b013e3181405b74.
- Rustin P., Munnich A., Rötig A. Succinate dehydrogenase and human diseases: new insights into a well-known enzyme. Eur. J. Hum. Genet. 2002; 10(5): 289–91. https://dx.doi.org/10.1038/sj.ejhg.5200793.
- Togashi S., Takahashi N., Iwama M., Watanabe S., Tamagawa K., Fukui T. Antioxidative collagen-derived peptides in human-placenta extract. Placenta. 2002; 23(6): 497–502. https://dx.doi.org/10.1053/plac.2002.0833.
- Заключение экспертизы Столичного центра юридической диагностики и судебной экспертизы. №16/14. М., 2014. [Zakliuchenie ekspertizy Stolichnogo tsentra yuridicheskoi diagnostiki i sudebnoi ekspertizy. N16/14. M., 2014. (in Russian)].
- Bairoch A., Apweiler R. The SWISS-PROT protein sequence data bank and its supplement TrEMBL. Nucleic Acids Res. 1997; 25(1): 31–6. https://dx.doi.org/10.1093/nar/25.1.31.
- Karasawa Y., Yukio I., Shigeru K., Yoshihide K., Hiroshi K., Kazuo K. et al. Melsmon clinical trial on insufficient milk secretion. Foundation Clinical. 2007; 15(3): Mar-81; 11–21.
- Karasawa Y., Iwasaki Y., Kagawa S., Saito M., Iwasaki Y., Kimura Y. et al. Clinical treatment test of Melsmon on menopausal disorder. Med. Treat. 1981; 9(3): 1–10.
- Клинические испытания эффективности и безопасности экстракта плаценты для женщин с симптомами менопаузы. Отчет о результатах клинического исследования, протокол № GM0703/P1–001. Сеул, Корея, 2008. (Предоставлен производителем Мелсмон Фармасьютикал Ко.Лтд., Япония). [Klinicheskie ispytaniya effektivnosti i bezopasnosti ekstrakta platsenty dlya zhenshchin s simptomami menopauzy. Otchet o rezul’tatakh klinicheskogo issledovaniya, protokol № GM0703/P1-001. Seoul, Korea, 2008. (Predostavlen proizvoditelem Melsmon Farmas’yutikal Ko.Ltd., Japan). (in Russian)].
- Park S.Y., Phark S., Lee M., Lim J.Y., Sul D. Anti-oxidative and anti-inflammatory activities of placental extracts in benzo[a]pyrene-exposed rats. Placenta. 2010; 31(10): 873–9. https://dx.doi.org/10.1016/j.placenta.2010.07.010.
- Коваленко И.И., Аталян А.В. Опыт применения гидролизата плаценты у женщин с климактерическим синдромом в перименопаузе. Гинекология. 2016; 18(5): 20–5. [Kovalenko I.I., Atalyan A.V. The experience of using the placenta hydrolyzate in women with climacteric syndrome in perimenopausal period. Ginecology/Ginekologiya. 2016; 18(5): 20–5.(in Russian)].
- Оразов М.Р., Радзинский В.Е., Хамошина М.Б. Опыт использования таргетной плацентарной терапии для коррекции менопаузальных симптомов. Хирургическая практика. 2016; 4: 45–53. [Surgical Practice/Khirurgicheskaya praktika. 2016; (4): 45–53. (in Russian)].
- Оразов М.Р., Хамошина М.Б., Бебнева Т.Н., Поликарпова С.Р. Возможности гидролизата плаценты человека в комплексном лечении симптомов генитоуринарного синдрома в постменопаузе. Гинекология. 2017; 19(1): 27–30. [Orazov M.R., Khamoshina M.B., Bebneva T.N., Policarpova S.R. The possibility of human placenta extract in the treatment of symptoms The possibility of human placenta extract in the treatment of symptoms genitourinary syndrome in postmenopausal women. Gynecology/Ginekologiya. 2017; 19(1): 27–30. (in Russian)]. https://dx.doi.org/10.26442/2079-5696_19.1.27-30.
- Царегородцева М.В., Новикова Я.С., Подолян О.Ф. Преждевременная недостаточность яичников: новые возможности терапии. Климактерий. 2016; 3: 26–31. [Tsaregorodtseva M.V., Novikova Ya.S., Podolyan O.F. Prezhdevremennaya nedostatochnost’ yaichnikov: novye vozmozhnosti terapii Klimakterii. 2016; (3): 26–31. (in Russian)].
- Покуль Л.В., Оразов М.Р., Лебедева М.Г., Бебнева Т.Н., Поликарпова С.Р. К вопросу о возможности аллогенной плацентарной терапии постовариоэктомических проявлений у больных, отягощенных гинекологическим раком, после противоопухолевого лечения. Гинекология. 2017; 19(2): 34–41. [Pokul L.V., Orazov M.R., Lebedeva M.G., Bebneva T.N., Polikarpova S.R. The possibility of allogeneic placental therapy of postovariectomical manifestations in patients with gynecological cancer after antitumor treatment. Gynecology/Ginekologiya. 2017; 19(2): 34–41. (in Russian)]. https://dx.doi.org/10.26442/2079-5696_19.2.34-41.
- Подзолков В.И., Никитина Т.И., Брагина А.Е., Подзолкова Н.М. Полиметаболические нарушения после гистерэктомии: случайность или закономерность? Рациональная фармакотерапия в кардиологии. 2011; 7(3): 294–9. [Podzolkov V.I., Nikitina T.I., Bragina A.E., Podzolkova N.M. Polymetabolic disorders after hysterectomy: a chance or a rule? Rational Pharmacotherapy in Cardiology/Ratsional’naya farmakoterapiya v kardiologii. 2011; 7(3): 294–9. (in Russian)].
- Оразов М.Р., Хамошина М.Б., Покуль Л.В., Бебнева Т.Н., Марапов Д.И., Поликарпова С.Р. Метаболическая терапия постгистерэктомического синдрома у женщин в перименопаузе. Фарматека. 2017; 12: 40–5. [Orazov M.R., Khamoshina M.B., Pokul L.V., Bebneva T.N., Marapov D.I., Polikarpova S.R. Metabolic therapy for posthysterectomic syndrome in perimenopausal women. Farmateka. 2017; (12): 40–5. (in Russian)].
- Кветной И.М., Клейменова Т.С., Родичкина В.Р., Дробинцева А.О., Полякова В.О., Цыпурдеева А.А., Оразов М.Р., Поликарпова С.Р. Экспрессия сигнальных молекул в эндометрии человека: оптимизация имплантационной восприимчивости под действием аллогенного гидролизата плаценты. Молекулярная медицина. 2018; 16(1): 37–43. [Kvetnoy I.M., Kleimenova T.S., Rodichkina V.R., Drobintseva A.O., Polyakova V.O., Tsypurdeeva A.A., Orazov M.R., Polikarpova S.R. Endometrium: optimization of the implantation susceptibility under the action of allogeneic placenta hydrolysate. Molecular Medicine/Molekulyarnaya meditsina. 2018; 16(1): 37–43. (in Russian)].пг
Received 03.02.2020
Accepted 07.02.2020
About the Authors
Inna A. Apolikhina, MD, PhD, Head of Department of Aesthetic Gynecology and Rehabilitation, National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov. Professor of Department of Obstetrics, Gynecology, Perinatology, and Reproductology, Institute of Professional Education, I.M. Sechenov First Moscow State Medical University (Sechenov University). Tel.: +7 (495)735-10-55. E-mail: apolikhina@inbox.ru/4, Oparina str., Moscow, 117997, Russian Federation; 8-2 Trubetskaya str., Moscow, 119991, Russian Federation.
Ayna S. Saidova, PhD, obstetrician-gynecologist of the Department of Aesthetic Gynecology and Rehabilitation, V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology. Tel.: +7 (926)206-60-51. E-mail: asekova14@yandex
4, Oparina str., Moscow, 117997, Russian Federation.
Igor I. Baranov, MD, PhD, Head of the organizational and methodological department of the scientific and organizational support service, National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov. E-mail: i_baranov@oparina4.ru
4, Oparina str., Moscow, 117997, Russian Federation
For citation: Apolikhina I.A., Saidova A.S., Baranov I.I. Use of placental therapy in the correction of functional impairments in women: investigations and clinical practice.
Akusherstvo i Ginekologiya/ Obstetrics and gynecology. 2020; 3: 203-10. (In Russian).
https://dx.doi.org/10.18565/aig.2020.3.203-210
Similar Articles
